. 2008 Nov 6;9:61. doi: 10.1186/1471-2296-9-61

Table 3.

Outcome measures – adjusted pairwise comparison of HCTZ monotherapy versus each fixed-dose combination therapy

	HCTZ fixed-dose combination therapy

Outcome measures	ARB/HCTZ	ACEI/HCTZ	BB/HCTZ
Persistence (Odds Ratio, 95% CI)	0.369^a (0.356, 0.383)	0.380^a (0.368, 0.393)	0.382^a (0.370, 0.395)
Adherence (Odds Ratio, 95% CI)	0.457^a (0.440, 0.475)	0.495^a (0.478, 0.513)	0.398^a (0.385, 0.412)
PDC at end of follow-up period (Odds Ratio, 95% CI)	0.388^a (0.374, 0.403)	0.415^a (0.402, 0.429)	0.435^a (0.421, 0.449)
MPR (HCTZ vs. fixed-dose)	44.4 vs 61.0 Δ = -16.6^b	44.6 vs 57.5 Δ = -12.9^b	44.5 vs 61.5 Δ = -17.0^b

^aSignificant difference in outcome measures between pairwise comparison with HCTZ users at p < 0.05.

^bp < 0.0001